Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Membrillo de Novales et al.,
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational..,
Preprints 2020, 2020050057, doi:10.20944/preprints202005.0057.v1 (Preprint)
166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 times when patients admitted in early stages. Early is relative to hospital admission here - all patients were in relatively serious condition.
risk of death, 55.1% lower, RR 0.45, p = 0.002, treatment 27 of 123 (22.0%), control 21 of 43 (48.8%), NNT 3.7.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Membrillo de Novales et al., 5 May 2020, retrospective, Spain, preprint, 19 authors, average treatment delay 7.0 days.
Abstract: Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020
doi:10.20944/preprints202005.0057.v2
Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an
observational study.
Membrillo FJ1,2**, Ramírez-Olivencia G*1,7, Estébanez M*1,7, de Dios B*1,7, Herrero MD*1,7, Mata
T*1,7, Borobia AM3, Gutierrez C4, Simón M5, Ochoa A6, Martinez Y1, Aguirre A8 , Alcántara F9,
Fernández P9, López E8, Valle P3, Campos S6, Navarro M7, Ballester E1, on behalf of the COVID19
Central Defense Hospital “Gómez Ulla” Team (annex 1)
1: CRBN & Infectious Diseases Unit. HLIU. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
2: Infectious Diseases Unit. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
3: Clinical Pharmacology Department. La Paz Hospital, Madrid, Spain.
4: Preventive Medicine Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
5: Microbiology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
6: Pneumology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
7: Internal Medicine Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
8: Ophthalmology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
9: Dermatology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain.
*contributed equally
**corresponding author. Francisco Javier Membrillo de Novales. CRBN & Infectious Diseases
Unit. Central Defense Hospital “Gómez Ulla”. Glorieta del Ejército, s/n, 28047 Madrid (Spain).
fmemnov@oc.mde.es
© 2020 by the author(s). Distributed under a Creative Commons CC BY license.
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020
doi:10.20944/preprints202005.0057.v2
Summary: Hydroxychloroquine has shown in vitro activity against SARS-CoV-2. Here we present
an observational study. We analysed data from 164 patients admitted to our hospital diagnosed
with COVID-19. Hydroxychloroquine treatment was associated with an increase in the mean
cumulative survival.
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020
doi:10.20944/preprints202005.0057.v2
ABSTRACT
Background: Although no specific treatment for COVID 19 has been proven effective yet, some
drugs with in vitro potential against SARS-CoV-2 virus have been proposed for clinical use.
Hydroxychloroquine has in vitro anti-viral and immunomodulatory activity, but there is no
current clinical evidence of its effectiveness on the outcome of the disease.
Methods: We enrolled all 18-85 years old inpatients from Central Defense Hospital, Madrid,
Spain, who were hospitalised due to COVID-19 and had a definitive outcome (either dead or
discharged). We used a statistical survival analysis.
Results: We analysed 220 medical records. 166 patients met the inclusion criteria. 48,8 % of
patients not treated with HCQ died, versus 22% in the group of hydroxychloroquine (p=0,002).
According to clinical picture at admission, hydroxychloroquine increased the mean cumulative
survival in all groups from 1,4 to 1,8 times. This difference was statistically significant in the mild
group.
Conclusions: in a cohort of 166 patients between 18 to 85 years hospitalised with COVID-19,
hydroxychloroquine treatment with an initial loading dose of 800mg improved patient survival
when admitted in early stages of the disease. There was a non-statistically significant trend
towards survival in all groups, which will need to be clarified in subsequent studies.
Type of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit